Overview

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.
Recent NewsMore >>
DateTitle 
11/28/16NantKwest to Present at the Piper Jaffray 28th Annual Health Care Conference
CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 28, 2016-- NantKwest Inc. (Nasdaq:NK) today announced that Company management will present at the Piper Jaffray 28th Annual Health Care Conference in New York, NY at 4:00 pm Eastern Time (ET) on Tuesday, November 29, 2016. NantKwest’s presentation will include a business overview and clinical update. Details are below: Piper Jaffray 28th Annual Healthcar... 
Printer Friendly Version
11/22/16Direct Injection of CAR-Engineered CD19.taNK Cells Demonstrating Potential “Vaccine” Protective Effect to be Highlighted in Oral Presentation at the 58th Annual Meeting of the American Society of Hematology
CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced that the Company’s abstract reviewing data on the company’s CD19.taNK program has been accepted for an oral presentation at the upcoming... 
Printer Friendly Version
11/22/16NantKwest Announces Landmark Study Published on high affinity haNK Cell Therapy in the Journal Oncotarget
Next Generation NK Cell Therapy Poised to Transition into Human Clinical Trials CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, announced in a paper published today in the journal Oncotarge... 
Printer Friendly Version
11/14/16NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors
Promising Clinically Meaningful Responses Seen Including a Radiological Complete Response in Early Data Analysis Presented at the 31st Annual Meeting of the Society for Immunotherapy of Cancer CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 14, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat can... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Past EventsMore >>
DateTitle
11/29/16 4:00 p.m. ET
Nantkwest Inc at Piper Jaffray 28th Annual Healthcare Conference
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.